All In Biotech

Drug Trial Radar · NCT07462377

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
EpiBiologicsIndustry
Sponsor type
Industry
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

Conditions

  • Epidermal Growth Factor
  • Epidermal Growth Factor Receptor
  • Epidermal Growth Factor Receptor Gene Mutation
  • Non Small Cell
  • Non Small Cell Lung
  • Non Small Cell Lung Cancer
  • Head and Neck
  • Head and Neck Cancer
  • Head and Neck Cancers
  • Head and Neck Squamous Cell Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma HNSCC
  • NSCLC (Non-small Cell Lung Cancer)
  • HNSCC
  • EGFR

Interventions

  • EPI-326Drug

    EPI-326 is a tissue-selective bispecific antibody for EGFR-driven cancers. EPI-326 will be administered in the clinic via IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the safety and tolerability of EPI-326Time frame: Up to 3 years.
  2. Determination of the recommended dose and schedule for EPI-326 administrationTime frame: Up to 3 years.

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 105 - START Los Angeles

    Los Angeles, California · Recruiting

  • Site 104 - START New Jersey

    East Brunswick, New Jersey · Recruiting

  • Site 107 - START New York - Long Island

    Lake Success, New York · Recruiting

  • Sarah Cannon and HCA Research Institute

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Site 102 - START San Antonio

    San Antonio, Texas · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)

    Kaohsiung City, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.